2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 367

Cytomegalovirus-Related Immunity Correlates With Myocardial Disease In Rheumatoid Arthritis
Abstract Number: 2907

D1398G Variant Of Hepatocyte Growth Factor Receptor – A Potential Biomarker Of Severe Interstitial Lung Disease In African American Scleroderma Patients
Abstract Number: 505

Damage Accrual In a Single Centre Cohort Of Patients With Primary Sjögren’s Syndrome Followed Up For Over 10 Years
Abstract Number: 2896

Damage In Systemic Lupus Erythematosus Is a Potentially Modifiable Outcome: Results From The Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Abstract Number: 535

Death Receptor 3 Increases Region-Specific, Osteoblast-Dependent Aberrant New Bone Formation In The Axial Skeleton Of Mice In a Spontaneous Model Of Ankylosing Enthesopathy
Abstract Number: 296

Declines In Levels Of Disease Activity and Physical Disability In Children With Juvenile Idiopathic Arthritis Seen In Standard Clinical Care Over The Last 25 Years
Abstract Number: 75

Decorin-Deficiency Alters Cartilage Stiffness and Attenuates The Development Of Osteoarthritis In Mice
Abstract Number: 1377

Decoy Receptor 3 Regulates the Expression of Tryptophan Hydroxylase TPH1 in Rheumatoid Synovial Fibroblasts
Abstract Number: 1628

Decreased Levels Of Splicing Factor 2 / Alternative Splicing Factor (SF2/ASF) Correlate With Lower Transcript Levels Of The RasGRP1 Normal Isoform In Lupus T Cells
Abstract Number: 1158

Decreased NK-Cell Numbers and Upregulation Of Markers Of Systemic Inflammation In Autoantibody –Positive Arthralgia Patients and Early Rheumatoid Arthritis Patients But Not In Autoantibody-Negative Rheumatoid Arthritis Patients
Abstract Number: 2072

Decreased Number Of Circulating NK Cells and Dramatic Lack Of IFN-Gamma Production In Patients With Antisynthetase Syndrome
Abstract Number: 936

Decreased Plasma Levels Of Soluble CD18 Link Leukocyte Migration and Disease Activity In Spondyloarthritis
Abstract Number: 1578

Decreased Sensitivity Of a Commercial Anti-dsDNA Assay In Patients With Moderately To Severely Active Systemic Lupus Erythematosus
Abstract Number: 1622

Deep-Sequencing Reveals Class-Specific Urinary Micrornas In Human Lupus Nephritis
Abstract Number: 35

Defective Regulatory Function Of Granzyme B-Producing B Cells In Patients With Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].